January 22, 2024Journal of Clinical OncologyOpen Access

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

View Full Paper

Ask AI

Bookmark

Abstract

Nivolumab plus chemotherapy did not significantly improve PFS versus chemotherapy in patients with EGFR-mutated metastatic NSCLC previously treated with EGFR TKIs. No new safety signals were identified.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mok et al. (2024) studied this question.

synapsesocial.com/papers/69d7485a58d71cbec648f643 https://doi.org/10.1200/jco.23.01017

View Full Paper

Ask AI

Bookmark

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Abstract

Discussion

Cite This Study

Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

Abstract

Discussion

Cite This Study

Keep reading

Keep reading